Why structured outcome measurement matters in knee OA care

Knee osteoarthritis affects an estimated 240 million people worldwide and ranks among the leading causes of disability globally — a scale that makes reproducible, per-patient outcome data not just useful but clinically necessary. Within such a large and heterogeneous population, even small differences in patient selection, disease severity, or follow-up practice can make results from one clinic difficult to compare with another. Robust outcome measurement is therefore foundational to any serious orthobiologic programme.

Mytocel MSK is designed from the outset as a protocol-driven procedure. Its clinical data collection framework — specified in the RegeneraActiva Worldwide SOP and intended to support consistent collection across participating clinics — anchors outcome tracking in a validated, widely recognised instrument rather than ad-hoc or informal scoring. That choice matters: standardised data can be audited, aggregated, and compared across sites, supporting both clinical governance and the accumulation of real-world evidence as the field develops.

The instrument selected for Mytocel MSK practice is the Knee Injury and Osteoarthritis Outcome Score (KOOS). Its five subscales — Pain, Symptoms, Activities of Daily Living, Sport and Recreation Function, and Knee-related Quality of Life — map directly onto the domains that matter most to patients with knee OA. By embedding KOOS within the procedure's formal SOP, Mytocel MSK gives participating clinics a framework for collecting a consistent, clinically meaningful data point from the moment of baseline assessment.

What KOOS measures and how its five subscales work

Across its five subscales, KOOS captures a deliberately broad picture of knee function. Symptoms covers joint-specific signs — swelling, grinding or clicking, catching, and stiffness — that patients may notice independently of pain. Pain assesses discomfort across a range of movements and loads, from walking on flat ground to twisting and pivoting. Activities of Daily Living (ADL) focuses on routine tasks such as descending stairs, rising from a chair, and putting on socks. Sport and Recreation extends the assessment to more demanding movement patterns: squatting, running, jumping, and cutting — domains that matter even to patients whose primary goal is to return to recreational activity rather than competitive sport. Knee-related Quality of Life addresses the broader impact: how often the patient is troubled by their knee, whether they have modified their lifestyle, and how much confidence they have in their joint.

All questions ask the patient to report symptoms over the preceding seven days. That fixed recall window is a deliberate design feature: it standardises the reporting period at every timepoint, making a T0 score directly comparable with a post-treatment score collected months later, rather than relying on patients to estimate an unspecified period.

Each subscale is scored independently on a 0–100 scale, where 100 represents no problems. Because the subscales are not collapsed into a single composite, a clinician can see, for example, that ADL function has improved whilst Sport and Recreation remains limited — the kind of domain-specific signal that shapes rehabilitation decisions.

The Mytocel MSK knowledge base contains KOOS forms in English, Spanish and Arabic. Clinics should confirm that they are using the appropriate validated and authorised language edition for their patient population rather than assuming that file availability alone establishes equivalence across sites.

How the Mytocel MSK SOP embeds KOOS at baseline

Designating KOOS completion at T0 — before any intervention — as a formal protocol step is one of the clearest governance decisions embedded in the Mytocel MSK Clinical Data Collection SOP, issued by RegeneraActiva Worldwide and available in both English and Spanish.

The SOP instructs clinics to avoid patient names in filenames and to use a date-of-birth-derived code. This is a filing convention that reduces direct use of names; it is not, by itself, proof of anonymisation or compliance with local data-protection requirements.

Within that folder, a three-subfolder structure — Consent, Diagnosis, and Reports — separates documentation type and places KOOS data in a consistently predictable location. The baseline KOOS report is filed under Reports using a standardised filename: YYMMDD_Report KOOS_T0. That timepoint code (_T0) makes the baseline record unambiguous and ensures that subsequent assessments, filed under the same convention at later timepoints, remain directly comparable across any participating clinic.

The sequencing of consent is equally deliberate. A signed RegeneraActiva Worldwide consent form must be completed before treatment begins, meaning T0 KOOS data is collected within a documented, consented framework — outcome measurement as a procedural precondition, not an administrative addition after the fact.

Taken together, the timepoint naming, folder structure and consent-first sequencing provide a practical framework for more consistent outcome documentation. Each clinic remains responsible for applying local governance, security and data-protection requirements.

KOOS within the full Mytocel MSK clinical data schema

Recording KOOS at T0 is one data point within a considerably richer baseline schema. The Mytocel MSK patient data spreadsheet organises each case so that KOOS subscale scores — held on a dedicated sheet, linked to the main record by patient number — sit alongside MRI findings, X-ray findings, Kellgren-Lawrence (KL) radiographic grading, and Outerbridge cartilage grading, all captured at the same baseline visit.

KL grading carries particular interpretive weight in this structure. Because the Tsoukas et al. 2023 prospective study (Bioengineering) recruited patients at KL grades 2–3, knowing a patient's KL grade at baseline situates any subsequent KOOS change within a defined disease-severity context — a meaningful distinction when comparing outcomes across a clinical dataset.

The schema also captures a panel of laboratory markers: HbA1c, ESR, vitamins D3 and B12, and a lipid profile. These systemic health variables support a whole-patient picture at baseline rather than a single-domain snapshot, and may help contextualise why patients with similar imaging grades report different functional scores.

It is worth keeping the evidence streams distinct: patient-reported KOOS changes and imaging data are recorded as separate fields, and one does not automatically confirm the other. That separation is a strength of the schema — it preserves the integrity of each data type, so that clinical interpretation at follow-up rests on evidence from multiple independent sources rather than a single measure interpreted in isolation.

KOOS in the Tsoukas 2023 prospective study

Tsoukas et al. 2023 (Bioengineering, 10, 1294) is the primary peer-reviewed publication for AMT® in knee osteoarthritis. It was a prospective observational study of 10 patients aged 37–84, with KOOS assessed before the procedure and at one and six months; imaging remained a separate evidence stream rather than a measure taken at every KOOS assessment point.

Across that population, the study reported patient-reported improvements in pain, mobility, and joint stiffness following the AMT® procedure. The authors concluded that autologous auricular cartilage micrografts obtained via Rigenera® technology represent an effective and safe protocol for early-stage knee OA and a valid treatment approach. Domain-by-domain KOOS subscale scores — the kind of detail that shows, for instance, whether ADL function moved independently of Sport and Recreation — are reported in full in Tsoukas D et al., Bioengineering 2023, 10, 1294; clinicians reviewing the evidence before adopting the procedure will find that subscale-level data there.

The same authors stated explicitly that their findings require validation in a larger patient population and in a randomised controlled trial. Generating that next tier of evidence depends on auditable, per-patient KOOS records collected at defined timepoints — which is precisely what the SOP's standardised data collection is built to produce. Clinic-generated KOOS data structured to the same measurement framework used in the peer-reviewed study can contribute meaningfully to that accumulating evidence base.

What consistent KOOS tracking builds for Mytocel MSK practice

Every KOOS record filed under a consistent timepoint convention can contribute to a more auditable clinical dataset. The date-of-birth-derived code reduces direct use of patient names, but clinics must still apply appropriate access controls, data minimisation and local privacy requirements before aggregating records across sites.

For the individual clinician, the value is immediate: consistently collected KOOS scores at defined timepoints create a documented outcome record presentable to patients, governance bodies, and peers without retrospective reconstruction. A well-governed outcome file is a practical form of professional accountability.

That value becomes clearest when set against the Tsoukas et al. 2023 findings. That study used KOOS as its principal patient-reported measure in a defined KL grade 2–3 cohort, reporting improvements in pain, mobility, and stiffness — and called explicitly for validation in larger populations and in a randomised controlled trial. Producing that next tier of evidence requires exactly what the SOP generates as standard: per-patient, timepoint-coded, imaging-linked KOOS data. Each case added to the international dataset, under a consistent schema, strengthens the foundation on which broader evidence can be built.

The practical next step is to confirm SOP adoption and select the appropriate KOOS language edition — the knowledge base contains English, Spanish and Arabic forms whose local suitability should be confirmed — matched to the patient population the clinic serves.